- * Participants on hemodialysis between the ages of 18 and 70 years, with serum potassium levels of at least 5.5 mmol/L
- * Adequately dialyzed (Kt/V ≥ 1.2)
Hyperkalemia
An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
NCT02033317 | PHASE 2 | INTERVENTIONAL
This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Investigator Site
Orlando,Florida,United States,32809
Investigator Site
Minneapolis,Minnesota,United States,55404
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov